LIFECORE BIOMEDICAL, INC. \DE\
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Income or loss per share
- Income or loss per share
Due to the Company’s net loss for all periods presented, the inclusion of dilutive securities would be antidilutive because it would reduce the amount of loss incurred per share. As a result, no additional dilutive shares were included in diluted loss per share, and there were no differences between basic and diluted loss per share.
The following securities on an as-converted basis were excluded from the computations of diluted loss per share:
| Three months endedSeptember 30, | Nine months endedSeptember 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Series A Preferred Stock | 7,825,882 | 7,131,888 | 7,825,882 | 7,131,888 |
| Stock options | 1,129,731 | 1,152,621 | 1,129,731 | 1,152,621 |
| RSUs | 1,460,078 | 1,377,482 | 1,460,078 | 1,377,482 |
| PSUs | 2,283,000 | 2,283,000 | 2,283,000 | 2,283,000 |
| Total | 12,698,691 | 11,944,991 | 12,698,691 | 11,944,991 |
See note 10 for more information about Series A Preferred Stock and note 12 for more information about stock options, restricted stock units (“RSUs”) and performance share units (“PSUs”).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.